跳转至内容
Merck

S8139

Sigma-Aldrich

舒林酸

≥98.0%

别名:

(Z)-5-氟-2-甲基-1-[4-(甲亚硫酰苯基)亚甲基]-1H-茚-3-醋酸

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C20H17FO3S
CAS号:
分子量:
356.41
EC號碼:
MDL號碼:
分類程式碼代碼:
12161501
PubChem物質ID:
NACRES:
NA.77

生物源

synthetic (organic)

化驗

≥98.0%

形狀

powder

技術

HPLC: suitable
gas chromatography (GC): suitable

溶解度

methanol: 50 mg/mL

應用

forensics and toxicology
veterinary

起源

Merck & Co., Inc., Kenilworth, NJ, U.S.

SMILES 字串

CC1=C(CC(O)=O)c2cc(F)ccc2\C1=C/c3ccc(cc3)S(C)=O

InChI

1S/C20H17FO3S/c1-12-17(9-13-3-6-15(7-4-13)25(2)24)16-8-5-14(21)10-19(16)18(12)11-20(22)23/h3-10H,11H2,1-2H3,(H,22,23)/b17-9-

InChI 密鑰

MLKXDPUZXIRXEP-MFOYZWKCSA-N

基因資訊

正在寻找类似产品? 访问 产品对比指南

相关类别

應用

处理人结肠癌细胞系可诱导 MRP1 和 MRP3,但不会诱导 MRP 家族的其他成员。据报道,可显着增加蒽环类药物(阿霉素、柔红霉素和表柔比星)以及替尼泊苷、VP-16 和长春新碱的细胞毒性。测试了舒林酸在体外对热诱导白蛋白变性的影响28,以及其与人血浆蛋白结合的能力。29

生化/生理作用

舒林酸是非甾体抗炎药,是具有抗增殖和凋亡作用的镇痛药。它抑制人结肠癌细胞中环氧合酶 2 的表达和活性25,26,并减轻腺瘤性息肉病患者的肿瘤负担。27
非甾体抗炎药;COX-1 的选择性抑制剂。

特點和優勢

该化合物是由Merck & Co., Inc., Kenilworth, NJ, U.S.开发的。想要浏览其他由制药公司开发的化合物以及已批准药物/候选药物清单, 请单击此处
这种化合物是ADME毒性研究的特色产品。点击此处发现更多特色ADME毒性产品。在sigma.com/discover-bsm可了解更多关于生物活性小分子的其他研究领域。

象形圖

Skull and crossbonesHealth hazard

訊號詞

Danger

危險分類

Acute Tox. 3 Oral - Repr. 2 - Resp. Sens. 1 - Skin Sens. 1

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable

個人防護裝備

Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Stephen X Skapek et al.
Pediatric blood & cancer, 60(7), 1108-1112 (2013-01-03)
Desmoid fibromatosis (desmoid tumor, DT) is a soft tissue neoplasm prone to recurrence despite complete surgical resection. Numerous small retrospective reports suggest that non-cytotoxic chemotherapy using tamoxifen and sulindac may be effective for DT. We evaluated the safety and efficacy
Caihua Zhu et al.
Stem cells (Dayton, Ohio), 30(10), 2065-2075 (2012-06-02)
Pharmacological targeting of breast cancer stem cells (CSCs) is highly promising for the treatment of breast cancer, as the small population of CSCs appears responsible for tumor initiation and progression and also for resistance to conventional treatment. Here we report
D E Duggan
Drug metabolism reviews, 12(2), 325-337 (1981-01-01)
Sulindac is a prodrug which, following absorption, rapidly attains a metabolic equilibrium with its active pharmacophore, the sulfide metabolite. At the level of the whole body, the reversible interconversion sulindac in equilibrium sulfide, and the differing distributional and excretory properties
N M Davies et al.
Clinical pharmacokinetics, 32(6), 437-459 (1997-06-01)
Sulindac is a nonsteroidal anti-inflammatory drug (NSAID) of the indene acetic acid class. The absorption of sulindac is rapid when given orally. Sulindac is reversibly metabolised to sulindac sulphide which has anti-inflammatory and analgesic properties and is irreversibly metabolised to
Nicole A Kratochwil et al.
Biochemical pharmacology, 64(9), 1355-1374 (2002-10-24)
In spite of the large amount of plasma protein binding data for drugs, it is not obvious and there is no clear consensus among different disciplines how to deal with this parameter in multidimensional lead optimization strategies. In this work

商品

Protein-based drug transporters are found in most tissues including liver, kidney, intestine, and brain. These transporters are particularly important in cancer treatment and multi-drug resistance research. Understanding the specific mechanisms of tumor cell transporters is becoming an essential aspect of chemotherapeutic drug design.

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门